Drug profile · INN
ciclesonide
ALVESCO 160
ciclesonide (ALVESCO 160) is a glucocorticoid receptor agonist. Associated with Chiesi Australia Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
Drug details — ciclesonide
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 4
- Programs
- 3
- Data quality
- 0.84
Quick answer
ciclesonide (ALVESCO 160) is a glucocorticoid receptor agonist. Associated with Chiesi Australia Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 9422327
Process for preparing crystalline ciclesonide with defined particle size
granted -
US 8486923
Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
granted -
US 8481516
Ciclesonide containing sterile aqueous suspension
granted -
US 8435497
Formoterol of and ciclesonide combination
granted
Frequently asked questions
What is ciclesonide?
ciclesonide (ALVESCO 160) is a glucocorticoid receptor agonist. Associated with Chiesi Australia Pty Ltd. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for ciclesonide?
ALVESCO 160 is a marketed brand name for ciclesonide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ciclesonide?
ciclesonide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.